Yong-Pyo Lee

Yong-Pyo Lee

Auto-generated profile, based on publicly available information

Yong-Pyo Lee

질병관리청 경북권질병대응센터 진단분석

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 June 2020 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
PDF file
JKJeong-Min Kim
Jeong-Min Kim
HKHeui Man Kim
Heui Man Kim
ELEun Jung Lee
Eun Jung Lee
HJHye Jun Jo
Hye Jun Jo
YYYoungsil Yoon
Youngsil Yoon
CYCheon Kwon Yoo
Cheon Kwon Yoo
Coronavirus Disease-19 (COVID-19) is a respiratory infection characterized by the main symptoms of pneumonia and fever. It is caused by the novel coronavirus severe acute respiratory syndrome Coronavirus-2 (SARS-CoV-2), which is known to spread via respiratory droplets. We aimed to determine the rate and likelihood of SARS-CoV-2 transmission from COVID-19 patients through non-respiratory routes. Serum, urine, and stool samples were collected from 74 hospitalized patients diagnosed with COVID-19 based on the detection of SARS-CoV-2 in respiratory samples. The SARS-CoV-2 RNA genome was extracted from each specimen and real-time reverse transcription polymerase chain reaction performed. CaCo-2 cells were inoculated with the specimens containing the SARS-COV-2 genome, and subcultured for virus isolation. After culturing, viral replication in the cell supernatant was assessed. Of the samples collected from 74 COVID-19 patients, SARS-CoV-2 was detected in 15 serum, urine, or stool samples. The virus detection rate in the serum, urine, and stool samples were 2.8% (9/323), 0.8% (2/247), and 10.1% (13/129), and the mean viral load was 1,210 ± 1,861, 79 ± 30, and 3,176 ± 7,208 copy/μL, respectively. However, the SARS-CoV-2 was not isolated by the culture method from the samples that tested positive for the SARS-CoV-2 gene. While the virus remained detectable in the respiratory samples of COVID-19 patients for several days after hospitalization, its detection in the serum, urine, and stool samples was intermittent. Since the virus could not be isolated from the SARS-COV-2-positive samples, the risk of viral transmission via stool and urine is expected to be low.

2 April 2025 in Public Health Weekly Report
Verified
Journal Article
Open access
PDF file
영하영란 하
영란 하
혜윤혜선 윤
혜선 윤
성차성경 차
성경 차
진이진희 이
진희 이
미권미림 권
미림 권
정전정훈 전
정훈 전
. Public Health Weekly Report 2025;18:618-20. https://doi.org/10.56786/PHWR.2025.18.15.2

12 May 2026
Verified
Journal Article
Open access
PDF file
영하영란 하
영란 하
명김명진 김
명진 김
혜윤혜근 윤
혜근 윤
혜정혜진 정
혜진 정
미권미림 권
미림 권
정전정훈 전
정훈 전
하영란, 김명진, 윤혜근, 정혜진, 권미림, 박윤아, 조정옥, 이용표, 문경란, 구보민, 전정훈. Public Health Weekly Report 2026;19:925-46. https://doi.org/10.56786/PHWR.2026.19.22.1

30 June 2023 in Osong Public Health and Research Perspectives
Verified
Journal Article
Open access
ISIn-Sook Shin
In-Sook Shin
YLYong-Pyo Lee
Yong-Pyo Lee
SLSeung-Hoon Lee
Seung-Hoon Lee
JLJae-Young Lee
Jae-Young Lee
JPJong-Ha Park
Jong-Ha Park
Yoon-Seok ChungYoon-Seok Chung
Yoon-Seok Chung
Objectives: In 2021, the effectiveness of the COVID-19 vaccine was analyzed among people living in the Honam region (Gwangju, Jeollanam-do, Jeollabuk-do, and Jeju) of the Republic of Korea. And we investigated changes in the dominant virus strain.Methods: This study used the data provided by the Korean Ministry of the Interior and Safety for individuals ≥12 years old in the Honam region, and the Integrated Disease and Health Management System of the Korea Centers for Disease Control and Prevention for COVID-19-vaccinated individuals as of December 31, 2021. Statistical analyzes were performed using IBM SPSS ver. 23.0. The occurrence of confirmed cases by vaccination status, the relative risk, and vaccine effectiveness by vaccine type were calculated.Results: In 2021, the COVID-19 vaccination rate in Honam was 88.6%. The overall vaccine effectiveness (after 2 and 3 doses) was 98.7% (p98%, and the effect among persons who received 2 doses was >90% regardless of the vaccine type. Although vaccine effectiveness decreased because of reduced antibody levels over time (as observed in breakthrough infections), receiving a booster dose restored the neutralizing antibody levels.